Tasigna (Nilotinib) Atherosclerosis Lawsuit 2026: MDL Status, Who May Qualify, and How Claims Work
Tasigna nilotinib atherosclerosis lawsuit 2026 guide: the alleged link to peripheral arterial disease, the US versus Canada warning gap, MDL 3006 basics, eligibility factors, and how claims generally work.